This article has been written and funded by the Boehringer Ingelheim & Lilly Alliance (Alliance) for UK and Irish healthcare professionals. Alliance products will be discussed at this meeting. The Alliance has provided funding towards the Diabetes Professional Care 2024 congress; however, it has had no input into the agenda, speaker selection, presentations or collateral content, except for this promotional symposium session.

The Alliance is committed to improving outcomes for people with type 2 diabetes and is delighted to be a Gold Sponsor of Diabetes Professional Care 2024. Come and join Consultant Interventional Cardiologist Dr Rahim Kanji and Practice Pharmacist Nadia Malik to discuss ‘Is this the final piece of the jigsaw: Improving outcomes for adult patients with T2D, HF and CKD’ at our sponsored symposium session on Wednesday 16th October.

Nadia Malik has worked in community pharmacy for 15 years. In 2021 she transitioned to primary care to join North Stockton PCN and she now works as the Practice Pharmacist at Queens Park Medical Centre. Recently, Nadia has helped set up a Diabetes Interest Group which facilitates upskilling and education of local healthcare professionals while providing a valuable support network.

Dr Rahim Kanji is a Consultant Interventional Cardiologist, working at Chelsea and Westminster Hospital NHS Foundation Trust and Imperial College Healthcare NHS Trust. He has an interest in the utility of biomarkers for thrombosis and fibrinolysis in the risk stratification of patients with cardiovascular disease and also in the use of digital technologies to provide innovative strategies to manage patients with cardiac disease. Currently, he is working on pathways to facilitate optimisation of patients with established cardiovascular disease, as well as prevention in the community.

For the ~3.96 million people in the UK currently diagnosed with type 2 diabetes plus the additional estimated 1.2 million people who are not yet diagnosed,(1) cardiorenal complications are among the most significant health risks.(2,3) Cardiovascular disease accounts for approximately one in four deaths for people with type 2 diabetes.(2) Furthermore, chronic kidney disease coexists in almost one-third of people with type 2 diabetes and is projected to become the fifth leading cause of years of life lost by 2040.(3,4)

It is a passion of the Alliance to ensure that as many of these patients as possible receive optimal care for their cardio-renal-metabolic conditions. To do this we believe we must support adoption and adherence to national treatment guidelines. Please join us at 12:00–13:00, Wednesday 16th October in Clinical Theatre 2 to hear from your colleagues and have your say on how this can be achieved.

References

1. Diabetes UK. How many people in the UK have diabetes? Available at: https://www.diabetes.org.uk/about-us/about-the-charity/our-strategy/statistics (accessed September 2024).

2. Pearson-Stuttard J et al. Lancet Diabetes Endocrinol. 2021:9(3):165–173.

3. Cook S et al. BMJ Open. 2023:13(3):eo65927.

4. Kovesdy CP. Kidney lnt Suppl (2011). 2022:12(1):7–11.

NP-GB-104963  |  October 2024